title: Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study.
abstract: Adolescent obesity is becoming a health problem in both developed and developing countries. Antiobesity drug therapy is not currently indicated for the treatment of adolescent obesity and remains investigational at this time. The aim of this study was to determine the efficacy and safety of sibutramine in obese adolescents. A randomized, double-blind, placebo-controlled trial, enrolling 60 adolescents, aged 14-17 yr, for 6 months was conducted. In the first month, all patients received placebo and a hypocaloric diet plus exercise orientation. For the next 6 months, participants received either sibutramine or placebo. Patients assigned to sibutramine group lost an average of 10.3 +/- 6.6 kg, and patients in placebo group lost 2.4 +/- 2.5 kg (P < 0.001). The mean body mass index reduction was significantly greater in the sibutramine group (3.6 +/- 2.5 kg/m(2)) than in the placebo group (0.9 +/- 0.9 kg/m(2); P < 0.001). No participant withdrew because of adverse events, and no difference in blood pressure or heart rate was noted between groups. There were no changes in echocardiographic parameters. In conclusion, sibutramine plus diet and exercise induced significantly more weight loss in obese adolescents.
authors.affiliation: Nutrology and Metabolism Department, Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione, Rua Visconde Silva, 52/704 Botafogo, 22271-090, Rio de Janeiro, Brazil. godoymatos@openlink.com.br
authors.forename: Amélio
authors.initials: A
authors.lastname: Godoy-Matos
authors.forename: Lucia
authors.initials: L
authors.lastname: Carraro
authors.forename: Andrea
authors.initials: A
authors.lastname: Vieira
authors.forename: Jucineia
authors.initials: J
authors.lastname: Oliveira
authors.forename: Erika P
authors.initials: EP
authors.lastname: Guedes
authors.forename: Lílian
authors.initials: L
authors.lastname: Mattos
authors.forename: Cristiane
authors.initials: C
authors.lastname: Rangel
authors.forename: Rodrigo O
authors.initials: RO
authors.lastname: Moreira
authors.forename: Walmir
authors.initials: W
authors.lastname: Coutinho
authors.forename: Jose Carlos
authors.initials: JC
authors.lastname: Appolinario
mesh_terms: D000293:Adolescent; D001067:Appetite Depressants / Q000008:administration & dosage* / Q000009:adverse effects; D001794:Blood Pressure; D015992:Body Mass Index; D001835:Body Weight; D003131:Combined Modality Therapy; D003503:Cyclobutanes / Q000008:administration & dosage* / Q000009:adverse effects; D004038:Diet, Reducing; D004311:Double-Blind Method; D004452:Echocardiography; D015444:Exercise; D005260:Female; D006339:Heart Rate; D006801:Humans; D008297:Male; D009765:Obesity / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D001067:Appetite Depressants; D003503:Cyclobutanes; C058254:sibutramine